Description:PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD140a has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Olaratumab in the sample competitively binds to the pre-coated protein with biotin-labeled Olaratumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Olaratumab bound in the initial step. The color development is stopped and the intensity of the color is measured. Stability and Storage:When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. Detection method:Colorimetric Sample type:Plasma, Serum Assay type:Quantitative Sensitivity:112.17 ng/mL Range:156.25 - 10,000 ng/mL Recovery:80-120% Background:Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody developed by Eli Lilly and Company. It selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR). With the trade name Lartruvo, olaratumab has been approved by USA, Canada, and European Union to use in combination with doxorubicin for the treatment of adults with advanced soft-tissue sarcoma (STS) who cannot be cured by cancer surgery or radiation therapy, and who have not been previously treated with doxorubicin. Shipping:2-8 ℃ Specifications:Olaratumab Note:For Research Use Only.